A woman in France dies from cardiovascular disease every seven minutes [1], resulting in approximately 200 deaths per day [2].
These statistics highlight a critical gap in public health awareness and medical treatment. While breast cancer often dominates the conversation regarding women's health, heart disease has become the leading cause of death for women in France.
Medical experts said gender bias and a lack of awareness are primary drivers of these mortality rates. This systemic issue extends into clinical research, where women represent less than 30% of participants in cardiology clinical trials [3]. This underrepresentation means that treatments and diagnostic criteria are often based on male physiology, leaving women at higher risk for misdiagnosis or ineffective care.
Efforts to bridge this gap have begun at both the local and international levels. In Vichy, a recent screening event saw 60 health professionals [4] provide free cardiovascular examinations to 130 women [5]. Such initiatives aim to identify risk factors early in populations that are frequently overlooked by standard cardiology protocols.
Financial investment is also shifting to address the research deficit. A fund of 25 million U.S. dollars was created specifically to support research into women's heart health [6]. This funding seeks to understand the unique ways cardiovascular disease manifests in women to improve survival rates and quality of life.
Addressing the mortality rate requires a shift in how health systems perceive female patients. By increasing the number of women in clinical trials and expanding free screening access, health officials said they hope to reduce the daily death toll and challenge the bias that characterizes heart disease as a primarily male condition.
“A woman in France dies from cardiovascular disease every seven minutes”
The disparity in cardiovascular outcomes for women in France suggests that clinical bias and a lack of gender-specific data are actively contributing to preventable deaths. Because medical standards were historically built on male subjects, women's symptoms are more likely to be overlooked, making targeted funding and inclusive clinical trials essential for reducing mortality.
